TargetBeta
PIK3CA
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha · also PI3K · Phosphatidylinositol 3-kinase family
14 programs in company-led studies act on PIK3CA, from 14 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Alpelisibrule | Novartis | phase 4 | 3711 running | – | ChEMBL |
| inavolisibrule | Hoffmann-La Roche | phase 3 | 2017 running | – | ChEMBL |
| tersolisib | Eli Lilly | phase 3 | 104 running | – | a judged reading |
| gedatolisibrule | Pfizer | phase 3 | 93 running | MTOR, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5 | ChEMBL |
| PI3K-alpha Inhibitor JS105rule | Risen (Suzhou) Pharma Tech | phase 3 | 11 running | – | NCIt |
| serabelisibrule | Takeda | phase 2 | 112 running | – | ChEMBL |
| risovalisibrule | Haihe Biopharma | phase 2 | 42 running | – | NCIt |
| zovegalisibrule | Relay Therapeutics | phase 2 | 22 running | – | NCIt |
| paxalisibrule | Kazia Therapeutics | phase 2 | 41 running | PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5 | ChEMBL |
| Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rule | Pikavation Therapeutics | phase 2 | 11 running | – | NCIt |
| Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636rule | Ensem Therapeutics | phase 2 | 11 running | – | NCIt |
| Mutant-selective PI3K-alpha Inhibitor RGT-490rule | Regor Pharmaceuticals | phase 1 | 11 running | – | NCIt |
| PI3Ka H1047R Mutant Selective Inhibitor CGT6297rule | Cogent Biosciences | phase 1 | 11 running | – | NCIt |
| RAS/PI3K-alpha Inhibitor VVD-159642rule | Bayer | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Breast Neoplasms, 9 programs
- Neoplasms, 4 programs
- Endometrial Neoplasms, 3 programs
- Colorectal Neoplasms, 2 programs
- Lymphatic Abnormalities, 2 programs
- Ovarian Neoplasms, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Clear-cell metastatic renal cell carcinoma, 1 program
- Glioblastoma, 1 program
- Neoplasm Metastasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026inavolisib · Hoffmann-La Roche · phase 3 · NCT03006172
- Jan 28, 2027Alpelisib · Novartis · phase 4 · NCT05038735
- Feb 2027paxalisib · Kazia Therapeutics · phase 2 · NCT07287202
- Apr 2027Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818 · Pikavation Therapeutics · phase 2 · NCT06736704
- Apr 30, 2027zovegalisib · Relay Therapeutics · phase 2 · NCT05216432
- Jun 30, 2027Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636 · Ensem Therapeutics · phase 2 · NCT06993844
- Aug 2027tersolisib · Eli Lilly · phase 3 · NCT07924930
- Aug 1, 2027RAS/PI3K-alpha Inhibitor VVD-159642 · Bayer · phase 1 · NCT06804824
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.